These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. First treatment for Pompe disease. FDA Consum; 2006 Dec; 40(4):3. PubMed ID: 17245826 [No Abstract] [Full Text] [Related]
28. Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Orlikowski D, Pellegrini N, Prigent H, Laforêt P, Carlier R, Carlier P, Eymard B, Lofaso F, Annane D. Neuromuscul Disord; 2011 Jul; 21(7):477-82. PubMed ID: 21550241 [Abstract] [Full Text] [Related]
29. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, van der Ploeg AT. Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987 [Abstract] [Full Text] [Related]
30. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, Jones SA, Olson R, White A, Wells C, Bali D, Case LE, Young SP, Rosenberg AS, Kishnani PS. Genet Med; 2012 Jan; 14(1):135-42. PubMed ID: 22237443 [Abstract] [Full Text] [Related]
38. Enzyme replacement for infantile Pompe disease: the first step toward a cure. Wagner KR. Neurology; 2007 Jan 09; 68(2):88-9. PubMed ID: 17210887 [No Abstract] [Full Text] [Related]